A pigment change should not be promised to reverse unless the evidence supports that promise. “Temporary” is an especially consequential word when a person is deciding whether to accept a visible adverse effect. A study average or another person's experience cannot guarantee an individual's course.
The current VYLEESI label describes focal hyperpigmentation and notes that resolution was not confirmed in all affected patients after discontinuation. It also associates more frequent exposure with greater concern. Those statements should not be turned into a home regimen intended to avoid pigment changes.
The FDA regulatory review examined pigmentation within the development program. Regulatory assessment considers the pattern, population and exposure context rather than treating every darkened area as the same event. This article reviewed indexed sections, not the complete underlying participant records.
There are two questions for a reader. One is whether a change could be related to treatment. The other is what the specific lesion or area represents clinically. A known adverse-effect category does not diagnose every new spot, and assuming a drug explanation can distract from an unrelated skin problem.
Useful information for a clinician includes location, timing, progression, previous appearance and concurrent exposures. Photographs may provide context, but lighting and image quality limit what can be concluded remotely. A dermatologist or treating clinician can decide what examination is needed.
The risk should also remain separate from effectiveness. Pigmentation does not measure improvement in desire or distress, and absence of pigment change does not establish lack of benefit. It is an adverse-effect question, not a potency test.
This article gives no prevention schedule and no prediction of when a change will fade. Someone using prescribed treatment should discuss new pigment changes with the prescriber rather than modify care based on a forum. Research-labelled PT-141 adds an identity uncertainty that the approved label cannot resolve. The evidence supports an informed safety conversation, including the possibility that reversibility is not assured, rather than a blanket cosmetic reassurance.